Aandeel CPMV MOSAIC IMMUNOENGINEERING, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Mosaic ImmunoEngineering, Inc.

Aandelen

CPMV

US61945M1018

Beurs gesloten - OTC Markets
Andere beurzen
 16:58:14 28-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,57 USD -1,71% Intraday-grafiek van Mosaic ImmunoEngineering, Inc. +3,64% -5,00%
14/05 Mosaic ImmunoEngineering, Inc. rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024 CI
19/04 Mosaic Immunoengineering, Inc. Kondigt het overlijden aan van Gloria Felcyn, Onafhankelijk Bestuurder en Lid van het Audit Committee, Compensation Committee en Corporate Governance and Nominating Committee CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
Mosaic Immunoengineering, Inc. Announces Demise of Gloria Felcyn, Independent Director and Member of Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K
Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)
Mosaic Immunoengineering, Inc. Announces Nicole Steinmetz, Ph.D., to Resign as A Member of the Board of Directors and Acting Chief Scientific Officer
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers CPMV
  4. Nieuws Mosaic ImmunoEngineering, Inc.
  5. Andere talen